TDMS Study 88032-05 Pathology Tables
NTP Experiment-Test: 88032-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXYMETHOLONE Date: 11/25/97
Route: GAVAGE Time: 07:12:49
27 WEEK SSAC
Facility: Battelle Columbus Laboratory
Chemical CAS #: 434-07-01
Lock Date: 01/02/96
Cage Range: All
Reasons For Removal: 25017 Scheduled Sacrifice
Removal Date Range: 10/21/93 - 10/22/93
Treatment Groups: Include 002 0 MG/KG
Include 004 3 MG/KG
Include 006 30 MG/KG
Include 008 100 MG/KG
Include 001 0 MG/KG
Include 003 3 MG/KG
Include 005 30 MG/KG
Include 007 150 MG/KG
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 88032-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXYMETHOLONE Date: 11/25/97
Route: GAVAGE Time: 07:12:49
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 3 MG/KG 30 MG/KG 100
MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 90 90 90 90
Scheduled Sacrifice 10 10 10 10
Early Deaths
Survivors
Animals Examined Microscopically 10 10 10 10
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
None
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
None
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
None
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
None
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 88032-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXYMETHOLONE Date: 11/25/97
Route: GAVAGE Time: 07:12:49
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 3 MG/KG 30 MG/KG 100
MG/KG
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
None
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
None
Page 3
NTP Experiment-Test: 88032-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXYMETHOLONE Date: 11/25/97
Route: GAVAGE Time: 07:12:49
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 3 MG/KG 30 MG/KG 150
MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 90 90 90 90
Scheduled Sacrifice 10 10 10 10
Early Deaths
Survivors
Animals Examined Microscopically 10 10 10 10
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
None
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Pituitary Gland (10) (10) (10) (10)
Pars Distalis, Adenoma 1 (10%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
None
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 88032-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXYMETHOLONE Date: 11/25/97
Route: GAVAGE Time: 07:12:49
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 3 MG/KG 30 MG/KG 150
MG/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
None
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
None
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
None
Page 5
NTP Experiment-Test: 88032-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXYMETHOLONE Date: 11/25/97
Route: GAVAGE Time: 07:12:49
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 3 MG/KG 30 MG/KG 150
MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 1
Total Primary Neoplasms 1
Total Animals with Benign Neoplasms 1
Total Benign Neoplasms 1
Total Animals with Malignant Neoplasms
Total Malignant Neoplasms
Total Animals with Metastatic Neoplasms
Total Metastatic Neoplasm
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------